Literature DB >> 11997397

The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents.

Jodi B Lubetsky1, Angeles Dios, Jialian Han, Bayan Aljabari, Bela Ruzsicska, Robert Mitchell, Elias Lolis, Yousef Al-Abed.   

Abstract

Macrophage migration inhibitory factor (MIF) is an immunoregulatory protein that is a potential therapeutic target for a number of inflammatory diseases. Evidence exists that an unexpected catalytic active site of MIF may have a biological function. To gain further insight into the role of the catalytic active site, a series of mutational, structural, and biological activity studies were performed. The insertion of an alanine between Pro-1 and Met-2 (PAM) abolishes a non-physiological catalytic activity, and this mutant is defective in the in vitro glucocorticoid counter-regulatory activity of MIF. The crystal structure of MIF complexed to (S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid methyl ester (ISO-1), an inhibitor of MIF d-dopachrome tautomerase activity, reveals that ISO-1 binds to the same position of the active site as p-hydroxyphenylpyruvic acid, a substrate of MIF. ISO-1 inhibits several MIF biological activities, further establishing a role for the catalytic active site of MIF.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11997397     DOI: 10.1074/jbc.M203220200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  110 in total

1.  Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast.

Authors:  Yoonsang Cho; Gregg V Crichlow; Jon J Vermeire; Lin Leng; Xin Du; Michael E Hodsdon; Richard Bucala; Michael Cappello; Matt Gross; Federico Gaeta; Kirk Johnson; Elias J Lolis
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-08       Impact factor: 11.205

Review 2.  D-dopachrome tautomerase (D-DT or MIF-2): doubling the MIF cytokine family.

Authors:  Melanie Merk; Robert A Mitchell; Stefan Endres; Richard Bucala
Journal:  Cytokine       Date:  2012-04-14       Impact factor: 3.861

3.  Receptor agonists of macrophage migration inhibitory factor.

Authors:  William L Jorgensen; Sunilkumar Gandavadi; Xin Du; Alissa A Hare; Alexander Trofimov; Lin Leng; Richard Bucala
Journal:  Bioorg Med Chem Lett       Date:  2010-09-29       Impact factor: 2.823

Review 4.  Scientific and clinical challenges in sepsis.

Authors:  Luis Ulloa; Michael Brunner; Laura Ramos; Edwin A Deitch
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

5.  Inhibition of macrophage migration inhibitory factor reduces diabetic nephropathy in type II diabetes mice.

Authors:  Zhigang Wang; Meng Wei; Meng Wang; Lei Chen; Hua Liu; Yi Ren; Kehui Shi; Hongli Jiang
Journal:  Inflammation       Date:  2014-12       Impact factor: 4.092

Review 6.  Harmful molecular mechanisms in sepsis.

Authors:  Daniel Rittirsch; Michael A Flierl; Peter A Ward
Journal:  Nat Rev Immunol       Date:  2008-10       Impact factor: 53.106

7.  Ostertagia ostertagi macrophage migration inhibitory factor is present in all developmental stages and may cross-regulate host functions through interaction with the host receptor.

Authors:  Guanggang Qu; Raymond Fetterer; Lin Leng; Xin Du; Dante Zarlenga; Zhiqiang Shen; Wenyu Han; Richard Bucala; Wenbin Tuo
Journal:  Int J Parasitol       Date:  2014-02-28       Impact factor: 3.981

Review 8.  MIF family cytokines in cardiovascular diseases and prospects for precision-based therapeutics.

Authors:  Pathricia V Tilstam; Dake Qi; Lin Leng; Lawrence Young; Richard Bucala
Journal:  Expert Opin Ther Targets       Date:  2017-07       Impact factor: 6.902

9.  Charge heterogeneity of bovine brain macrophage migration inhibitory factor.

Authors:  O A Cherepkova; E M Lutova; B Ya Gurvits
Journal:  Neurochem Res       Date:  2005-01       Impact factor: 3.996

Review 10.  Mechanisms of macrophage migration inhibitory factor (MIF)-dependent tumor microenvironmental adaptation.

Authors:  Beatriz E Rendon; Sharon S Willer; Wayne Zundel; Robert A Mitchell
Journal:  Exp Mol Pathol       Date:  2009-01-07       Impact factor: 3.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.